CLAIMS

1. A composition comprising a first peptide of SEQ ID NO: 1 or a peptide having at least 90% identity to SEQ ID NO: 1, and a second peptide of SEQ ID NO: 2 or a peptide having at least 90% identity to SEQ ID NO: 2, wherein said two peptides are not linked to each other.
2. The composition of claim 1, wherein if the composition comprises a peptide having at least 90% identity to SEQ ID NO: 1 and/or a peptide having at least 90% identity to SEQ ID NO: 2, the glutamine (Q) residue at position 13 in the peptide of SEQ ID NO: 1 remains unchanged in the amino acid sequence of the peptide having at least 90% identity to SEQ ID NO: 1, and the tyrosine (Y) residue at position 18 in the peptide of SEQ ID NO: 2 either remains unchanged in the amino acid sequence of the peptide having at least 90% identity to SEQ ID NO: 2 or is replaced by a serine (S).
3. A set of components, or composition, comprising nucleic acids allowing the expression of two peptides which are not linked to each other, wherein a first nucleic acid comprises a sequence encoding a peptide of SEQ ID NO: 1 or a peptide having at least 90% identity to SEQ ID NO: 1, and a second nucleic acid comprises a sequence encoding a peptide of SEQ ID NO: 2, or a peptide having at least 90% identity to SEQ ID NO: 2.
4. A set of components, or composition, comprising vectors allowing the expression of two peptides which are not linked to each other, wherein a first vector comprises a sequence encoding a peptide of SEQ ID NO: 1 or a peptide having at least 90% identity to SEQ ID NO: 1, and a second vector comprises a sequence encoding a peptide of SEQ ID NO: 2, or a peptide having at least 90% identity to SEQ ID NO: 2.
5. A cell or composition comprising said cell and an acceptable support, wherein the cell allows the expression of two peptides which are not linked to each other and wherein the cell comprises a first nucleic acid sequence or vector encoding a peptide of SEQ ID NO: 1, or a peptide having at least 90% identity to SEQ ID NO: 1, and a second nucleic acid sequence or vector encoding a peptide of SEQ ID NO: 2, or a peptide having at least 90% identity to SEQ ID NO: 2.
6. The composition of anyone of claims 1-5, wherein the composition further comprises at least one additional active compound, preferably an active compound efficient against pain, even more preferably a SAID, NSAID or opioid drug.
7. The composition of anyone of claims 1-6, wherein the composition comprises a pharmaceutically and/or dietetically acceptable support.
8. The composition of anyone of claims 1-7 wherein the composition further comprises ascorbic acid or a ascorbic acid salt.
9. A set of a first peptide of SEQ ID NO: 1 or a peptide having at least 90% identity to SEQ ID NO: 1 and a second peptide of SEQ ID NO: 2 or a peptide having at least 90% identity to SEQ ID NO:

2, wherein said two peptides are not linked to each other, the set of claim 3 or 4, the composition of any one of claims 1-8, or the cell of claim 5, wherein the set, composition or cell is for use as a medicament in a subject in need thereof.

10. A set of a first peptide of SEQ ID NO: 1 or a peptide having at least 90% identity to SEQ ID NO: 1 and a second peptide of SEQ ID NO: 2 or a peptide having at least 90% identity to SEQ ID NO: 2, wherein said two peptides are not linked to each other, the set of claim 3 or 4, the composition of any one of claims 1-8, or the cell of claim 5, wherein the set, composition or cell is for use in preventing or treating pain in a subject in need thereof.
11. Use of a set of a first peptide of SEQ ID NO: 1 or a peptide having at least 90% identity to SEQ ID NO: 1 and a second peptide of SEQ ID NO: 2 or a peptide having at least 90% identity to SEQ ID NO: 2, wherein said two peptides are not linked to each other, the set of claim 3 or 4, the composition of any one of claims 1-8, or the cell of claim 5, in the manufacture of a medicament for preventing or treating pain in a subject in need thereof.
12. The set, the composition or the cell for use according to claim 10, or the use according to claim 11, wherein pain is a chronic pain, a neuropathic pain, a postoperative pain, an inflammatory pain, an arthritic pain, pain associated with damage to joints, pain related to Ehlers-Danlos syndrome, pain resulting from sun burn, pain resulting from ice burn, hyperalgesia, allodynia, or acute pain.
13. The set, the composition or the cell for use according to any one of claims 9, 10 or 12, or the use according to claim 11 or 12, wherein the subject is a mammal, in particular a human being.
14. The set or the composition for use according to any one of claims 9-10 and 12-13, or the use according to any one of claims 11-13, wherein the composition is to be administered intramuscularly, intravenously, intraperitoneally, orally (*per os*), anally, cutaneously, subcutaneously, topically, dermically, transdermically or intrathecally to the subject, preferably subcutaneously or orally.
15. The set or the composition for use according to any one of claims 9-10 and 12-14, or the use according to any one of claims 11-14, wherein the set or composition comprises between 1µg and 100 mg, preferably between 25 µg and 10 mg, of both the first and second peptides per unit dose.
16. The set or the composition for use according to any one of claims 9-10 and 12-15, or the use according to any one of claims 11-15, wherein said set or composition is to be administered at a dose between 1 µg/kg/day and 100 mg/kg/day, preferably between 2.5 µg/kg/day and 0.6 mg/kg/day, for a mammal.
17. A kit comprising i) a first peptide of SEQ ID NO: 1or a peptide having at least 90% identity to SEQ ID NO: 1, or a nucleic acid sequence encoding said peptide, ii) a second peptide of SEQ ID NO: 2 or a peptide having at least 90% identity to SEQ ID NO: 2, or a nucleic acid sequence encoding said peptide, the first and second peptides, or the nucleic acids encoding said peptides, being in distinct containers, and optionally iii) written instructions for using the kit.